York Gwill 4
4 · Alto Neuroscience, Inc. · Filed May 14, 2026
Research Summary
AI-generated summary of this filing
Alto Neuroscience (ANRO) Director York Gwill Receives Award of 10,958 Options
What Happened York Gwill, a director of Alto Neuroscience, was granted a derivative award (an option) to acquire 10,958 shares on May 12, 2026. The reported acquisition price is $0.00 (the award was not purchased), so the immediate cash value reported is $0. This was an award under the company’s director compensation program, not an open-market purchase or sale.
Key Details
- Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (timely filing).
- Security: derivative/option covering 10,958 shares; reported price $0.00 and Reporting Person paid no consideration (per filing).
- Vesting: Shares underlying the option vest on the earlier of the one-year anniversary of the grant or the issuer’s next annual meeting, subject to continuous service (Footnote F1).
- Source: Issued under the Issuer’s Non-Employee Director Compensation Policy; not sold to the director (Footnote F2).
- Shares owned after transaction: Not disclosed in the filing.
Context This was a compensation award (option grant) to a non-employee director—common corporate practice—rather than a buy or sale signaling a trading view. The option vests over time, which limits immediate disposition. Because the filing reports an award (code A) and not a market purchase or sale, it should be treated as routine director compensation rather than an insider investment signal.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F2][F1]2026-05-12+10,958→ 10,958 totalExercise: $24.63Exp: 2036-05-11→ Common Stock (10,958 underlying)
Footnotes (2)
- [F1]The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.
- [F2]This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.